News



31/Mar/2020

The Seventh Annual Advances in Chemical Sciences Symposium Royal Sonesta Hotel Cambridge, MA: May 4th, 2018 A day-long symposium focused on Medicinal Chemistry, Organic Synthesis, and Methodology, featuring eminent scientists from industry and academia. Speakers: Professor Richard R. Schrock (MIT): “TBA” Professor Dale L. Boger (Scripps Research Institute): “Redesign of Vancomycin for Resistant Bacteria” Professor Laura Kiessling (MIT): “TBA” Dr. Sue Ashwell (Forma Therapeutics): “Discovery and Optimization of a Novel Series of Inhibitors of mt-IDH1” Dr. Michael Hoemann (Abbvie): “Discovery and Optimization of Spleen Tyrosine Kinase Inhibitors for Immunological Diseases” Dr. Frank Salituro (Sage Therapeutics): “Discovery and Clinical Development of SAGE-217: A Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (GABA)A Receptor” Plus: Vendor Exhibition Hall and Networking Reception


31/Mar/2020

Sharp Edge Labs, Inc., http://www.sharpedgelabs.com a drug discovery biology firm, and Creagen Biosciences Inc. http://www.creageninc.com a medicinal chemistry firm, today announced that they have entered into a compound library screening agreement to test Creagen’s medicinal chemistry compound libraries in Sharp Edge Labs’ biological screening assays. The agreement covers all libraries in the Creagen collection and will be applied to Sharp Edge Labs screening assays across therapeutic areas, including, Parkinson’s, Alzheimer’s, Cancer, Cystic Fibrosis and Lysosomal Storage Disorders.

Scott Sneddon, PhD, J.D., President and CEO of Sharp Edge Labs noted that this was a unique opportunity to bring Creagen’s compounds into Sharp Edge Labs’ trafficking assays, and to probe previously unexploited miolecular mechanisms for these diseases. The agreement is open-ended, with additional compounds being made available and additional screening assays being offered by agreement of the companies. “We’re excited to test Creagen’s compounds across a portfolio of first-in-class cellular trafficking assays using our technology’” Sneddon said. “These assays probe novel biology, and expose molecular targets not previously exploited in drug discovery programs.” Sneddon said. Prior to co-founding Sharp Edge Labs, Sneddon was part of the Drug Discovery program at Genzyme Corp., where he oversaw numerous similar compound library screening collaborations.

 


31/Mar/2020

Industrial postdoctoral and researcher scientist positions are available in our medicinal chemistry division.

The project will involve design and optimization of flexible synthetic strategies for preparation of small molecules for oncology research.

The applicants must have:

  • PhD in Organic/medicinal chemistry
  • 1-2 year’s prior postdoctoral experience
  • a competitive publication record
  • strong knowledge in modern synthetic organic/medicinal chemistry and analytical chemistry.

Previous experience working with parallel library synthesis, DNA encoded libraries and antibody-drug-conjugate (ADC) is desirable.

Entry level postdoctoral researchers will be considered and those with advanced postdoctoral training could be eligible for a Research scientist position.

Send resume and contact information with references to: anny@creageninc.com.

Also visit: http://www.creageninc.com


31/Mar/2020

CreaGen positions itself for further growth by expanding its current products' business to better meet the growing demands of the industry to obtain difficult to find and make organic and organometallic compounds. WOBURN, MA -- CreaGen Biosciences is a specialty drug discovery chemistry service company ("CreaGen"), today announced its next step in meeting the growing demands of the drug discovery industry by acquiring Prime Organics' Catalogue Business. Prime Organics closed its doors after almost 20 years of business this May. Acquiring Prime's Catalogue Business, demonstrates CreaGen's continued evolution to respond to the demands of the industry in turn response to the industry's need to find it extremely challenging to obtain difficult to find and complex organic and organometallic compounds to make. CreaGen will continue to provide their clients their full range of drug discovery chemi


31/Mar/2020

March 24, 2014, The State Room, Boston, MA
CreaGen Biosciences and CreaGen Chemistry Incubator (C2I) are sponsors of the Redefining Early Stage Investments, a quarterly ongoing conference series that will be establishing a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding. These events will give early stage life science companies the chance to start, resume or close conversations with relevant investors, creating a global dialogue to bring products to market at a faster pace. Visit CreaGen Biosciences and CreaGen Chemistry Incubator (C2I) booth at this event to learn more about our services and facility. http://www.resiconference.com 


31/Mar/2020

December 29, 2013 (PressRelease) – Creagen Biosciences hails the success of its 10 year world-class services organization, is pleased to announce a competitive discounted rate for all future projects of 5 FTEs or greater during Q1 2014. "This special offer is our way of saying thanks to all our loyal patrons that have supported us during our first 10 years," commented, Raj Rajur, CEO, President and Founder, CreaGen Biosciences."




Subscribe


Sign up for CreaGen Inc newsletter to receive all the news.




Social networks



Twitter

#WeCare




Contact us




Send us an email

rrajur@creageninc.com



Subscribe


Sign up for Medicare newsletter to receive all the news offers and discounts from Medicare eye clinic.




Social networks



Twitter

#WeCare





© CreaGen Inc 2019. All rights reserved. Designed by Inqude



© CreaGen Inc 2019. All rights reserved. Designed by Inqude